• About Us
    • Àtẹ́lẹwọ́ Podcast
  • Contact
  • Cookie Policy
  • Disclaimer
  • Privacy Policy
  • Sitemap
Freelanews
Advertisement
  • Home
  • News
    • Crime
  • Business
  • Brands
  • Banking
  • Opinion
  • Interview
  • Entertainment
  • Podcast
    • Àtẹ́lẹwọ́
  • Sports
  • Events
No Result
View All Result
  • Home
  • News
    • Crime
  • Business
  • Brands
  • Banking
  • Opinion
  • Interview
  • Entertainment
  • Podcast
    • Àtẹ́lẹwọ́
  • Sports
  • Events
No Result
View All Result
Freelanews
No Result
View All Result
Home General

Coronavirus: Human trial of vaccine shows promising results in China

Freelanews by Freelanews
June 5, 2020
in General
0
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0

An experimental vaccine developed in China has been found to be safe and able to generate an immune response against SARS-CoV-2, the virus that causes COVID-19.

According to a new research published in The Lancet, the early-stage trial was conducted by researchers at several laboratories and included 108 participants aged 18 to 60.

A report on The New York Times, indicates that those who received a single dose of the vaccine produced certain immune cells, called T cells, within two weeks. Antibodies needed for immunity peaked at 28 days after the inoculation.

The trial is the first step in testing the vaccine and was intended mainly to verify its safety.

Proof of its effectiveness will, however, require trials in thousands, perhaps hundreds of thousands, more people.

A vaccine for COVID-19 is considered to be the best long-term solution for allowing countries to reopen their economies and return to normalcy.

American business magnate, Bill Gates, had said it could take as long as two years or at least nine months before a vaccine can be found to tackle the deadly coronavirus pandemic that has claimed thousands of lives across the globe.

Mr Gates said as of April 9, 115 different COVID-19 potential vaccines were being developed globally.

Vaccine trial

The vaccine reported on Friday was made with a virus, called Ad5, modified to carry genetic instructions into a human cell.

The cell begins making a COVID-19 protein; the immune system learns to recognise the protein and attack it, in theory preventing the virus from ever gaining a foothold.

But Ad5 is a cold virus that many people probably have already been exposed to. About half of the participants in the trial had powerful antibodies to Ad5 before they got the vaccine.

In these people, “their immune systems will essentially rear up and blunt the effect of the vaccine,” said Kirsten Lyke, a vaccinologist at the University of Maryland who is leading another COVID-19 vaccine trial.

The researchers in China did find that people who had Ad5 antibodies were less likely to develop a strong immune response to the vaccine.

Peter Hotez, dean of the National School of Tropical Medicine at Baylor College of Medicine, said “That may limit the use of this vaccine.

“If you are comparing vaccines, the adenovirus ones so far seem to be on the lower end of the spectrum.”

Other teams have turned to adenoviruses to develop COVID-19 vaccines, but they are using less common strains, or even animal strains, to circumvent this problem.

Dan Barouch, who is working on an Ad26 vaccine, said his team has data from Africa and Southeast Asia showing that people generally do not have high levels of antibodies to that strain.

Only a subset of people in the new trial produced neutralizing antibodies to the virus, the kinds of molecules needed for immunity. Other vaccine candidates have reported better results in the levels of neutralising antibodies.

Weaker immunity

People between 45 and 60 years of age are said to have produced weaker immune responses following vaccination than younger participants.

Ms Lyke said the responses may turn out to be even weaker among people older than 60.

“That’s a very important target population that they would have to examine,” she said.

Ms Lyke suggested that this vaccine might be best suited to younger populations and children.

The results are based on data from a short period, and it is unclear how long the vaccine’s protection might last.

The researchers tested three doses and said the highest dose seemed to be the most effective.

Experts said this dose-response is encouraging. Unfortunately, people who got the highest dose also experienced the most side effects.

coron

About 80 per cent of the participants reported at least one side effect, all expected with a viral vaccine, experts said.

Apart from pain at the injection site, close to half of the participants reported fever, fatigue and headaches, and about one in five had muscle pain.

Experts praised the researchers for publishing all of their data for others to review and said the results were promising overall.

“What we hope is that there will be not one vaccine but several vaccines that will be approved,” Mr Barouch said.

He said the world needs multiple vaccines.

Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
freelanews
Freelanews

Freelanews is a potpourri of news, entertainment, business, events and photos. This is no fake news.


Discover more from Freelanews

Subscribe to get the latest posts sent to your email.

Related Posts

freelanews MG 1178 85 scaled 1
General

9ice’s Surprise Birthday Party Featured Celebrities and Happiness (Video, Photos)

by Freelanews
January 18, 2020
map of oyo
General

PDP, APC clash Three die in Oyo State

by Oreoluwa Ojelabi
March 17, 2023
blog image 33
General

Take a tour of these Pisco vineyards to indulge in Peru

by Freelanews
September 11, 2018
blog image 47
General

It’s Almost Wearing Season: Try These T-shirts For Size

by Freelanews
September 11, 2018
Image 2023 09 26 at 095727 jpg
General

LASEPA commits to tough environmental enforcement

by Freelanews
September 26, 2023

Discussion about this post

ADVERTISEMENT

Recent News

Makinde

Makinde receives strong push for 2027 presidential bid

October 8, 2025
Rotary Club cataract surgery

Rotary Club cataract surgery transforms 30,000 lives

October 8, 2025
Ikechukwu N arrest

Ikechukwu N arrest shocks Argentina after INTERPOL raid

October 8, 2025
CBN monetary stability

CBN assures Nigerians of monetary stability progress

October 8, 2025

Search

  • Trending
  • Comments
  • Latest
Political persecution in Ogun State

Political persecution in Ogun State: Abiodun moves against Otunba Gbenga Daniel with demolition threats again

August 9, 2025
Abdul-Muiz Olanrewaju Animashaun

Abdul-Muiz Olanrewaju Animashaun remembered with love

September 14, 2025
Taylor Swift deepfake scandal

Taylor Swift faces deepfake scandal as Swifties call for stricter regulation

January 25, 2024
April Wind Couture

April Wind Couture thrives in Nigeria’s tough economy with bold Ankara vision

September 12, 2025
amoke

‘Meals by Amoke’ We serve traditional dishes in a modern way, Bukoye Fasola reveals

0
Image 2024 03 26 at 120645 AM jpeg

Charles Inojie, Ali Nuhu call on communities to #MakeWeHalla against domestic violence

0
Meran Primary Health Centre

Lagos father shares heartbreaking experience at Meran Primary Health Centre (Photos)

0
fls2

‘Disarticulated system’ Gov’t confused about Nigerian education, expert laments

0
Makinde

Makinde receives strong push for 2027 presidential bid

October 8, 2025
Rotary Club cataract surgery

Rotary Club cataract surgery transforms 30,000 lives

October 8, 2025
Ikechukwu N arrest

Ikechukwu N arrest shocks Argentina after INTERPOL raid

October 8, 2025
CBN monetary stability

CBN assures Nigerians of monetary stability progress

October 8, 2025
October 2025
MTWTFSS
 12345
6789101112
13141516171819
20212223242526
2728293031 
« Sep    
Freelanews

Freelanews is a Nigerian digital news platform that delivers timely, credible, and engaging stories across politics, business, entertainment, lifestyle, and the creative industry, with a strong focus on promoting innovation, integrity, and inclusivity in storytelling.

Follow Us

  • Facebook
  • TikTok
  • YouTube
  • Instagram

Editor’s Pick

  • OGD vs DA
    OGD vs DA: The real story never told
    • August 22, 2025
  • Toyota Sienna harassment
    Why is Lagos State govt harassing Toyota Sienna users?
    • August 19, 2025
  • Otunba Gbenga Daniel
    Who really is Otunba Gbenga Daniel?
    • August 18, 2025

Hot!

Makinde

Makinde receives strong push for 2027 presidential bid

October 8, 2025
Rotary Club cataract surgery

Rotary Club cataract surgery transforms 30,000 lives

October 8, 2025
No Result
View All Result
  • About Us
  • Contact
  • Advertisement
  • Sitemap

© 2025 Freelanews | by Iretura.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In

Add New Playlist

Total
0
Share
0
0
0
0
0
0
No Result
View All Result
  • Home
  • News
    • Crime
  • Business
  • Brands
  • Banking
  • Opinion
  • Interview
  • Entertainment
  • Podcast
    • Àtẹ́lẹwọ́
  • Sports
  • Events

© 2025 Freelanews | by Iretura.

This website uses cookies. By continuing to use this website you are giving consent to cookies being used. Visit our Privacy and Cookie Policy.

Discover more from Freelanews

Subscribe now to keep reading and get access to the full archive.

Continue reading